Scholarlink

<p>Schizophrenia is associated with widespread gray matter reduction. This is influenced by the underlying connectivity, resulting in covarying patterns of structural changes that are more pronounced in treatment-resistant individuals. However, it remains uncertain whether a distinct network&#xa0;of brain regions, with specific neurotransmitter basis, forms the substrate for treatment resistance in schizophrenia. We investigated the structural covariance networks (SCN) in 198 individuals; 55 with treatment-resistant schizophrenia (TRS) and 79 without TRS (non-TRS) in active symptomatic phase, and 64 healthy controls (HC) using Calhoun’s Source-Based Morphometry. We mapped the putative neurotransmitter basis of the SCNs using a PET-based chemoarchitectural atlas. Twelve independent components (i.e., SCNs) were identified. A prefrontal-limbic SCN had lower gray matter volume (GMV) in TRS compared to HC and non-TRS (<i>F</i> = 7.757, <i>p</i> &lt; 0.001, FDR-corrected). Spatial correlation with chemoarchitectural atlas revealed predominant contributions from serotonergic [5HT<sub>1b</sub> and 5HT<sub>2a</sub>], glutamatergic [mGluR<sub>5</sub>], histaminergic [H<sub>3</sub>], and opioid [MOR] receptors for this&#xa0;TRS-related SCN (all <i>p</i><sub>spin-permutation</sub> &lt; 0.05, FDR-corrected). A different&#xa0;SCN comprised of dorsal fronto-temporal and parieto-occipital regions, not&#xa0;associated with &#xa0;any specific neurotransmitter distribution, exhibited reduced GMV in both TRS and non-TRS groups&#xa0;vs. HC (<i>F</i> = 7.239, <i>p</i> &lt; 0.001, FDR-corrected). Amidst the generic GMV reduction that is shared with non-TRS patients, patients with TRS have specific prefrontal-limbic structural deficits with a unique non-dopaminergic chemoarchitecture. These findings indicate a putative molecular and structural basis for poor treatment response, guiding the development of second- and third-line pharmacotherapies for TRS.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Distinct structural deficits in treatment-resistant schizophrenia and their putative neurotransmitter basis: a source-based morphometry analysis

  • 期刊论文

  • 发表日期：

    2025年5月28日

查看全文
  • Huan Huang,
  • Xiaowei Wang,
  • Xuan Qin,
  • Rui Xu,
  • Ying Xiong,
  • Cheng Chen,
  • Qirong Wan,
  • Hao Liu,
  • Chang Shu,
  • Wei Yuan,
  • Yunlong Peng,
  • Yuan Zhou,
  • Huiling Wang,
  • Lena Palaniyappan

摘要

Schizophrenia is associated with widespread gray matter reduction. This is influenced by the underlying connectivity, resulting in covarying patterns of structural changes that are more pronounced in treatment-resistant individuals. However, it remains uncertain whether a distinct network of brain regions, with specific neurotransmitter basis, forms the substrate for treatment resistance in schizophrenia. We investigated the structural covariance networks (SCN) in 198 individuals; 55 with treatment-resistant schizophrenia (TRS) and 79 without TRS (non-TRS) in active symptomatic phase, and 64 healthy controls (HC) using Calhoun’s Source-Based Morphometry. We mapped the putative neurotransmitter basis of the SCNs using a PET-based chemoarchitectural atlas. Twelve independent components (i.e., SCNs) were identified. A prefrontal-limbic SCN had lower gray matter volume (GMV) in TRS compared to HC and non-TRS (F = 7.757, p < 0.001, FDR-corrected). Spatial correlation with chemoarchitectural atlas revealed predominant contributions from serotonergic [5HT1b and 5HT2a], glutamatergic [mGluR5], histaminergic [H3], and opioid [MOR] receptors for this TRS-related SCN (all pspin-permutation < 0.05, FDR-corrected). A different SCN comprised of dorsal fronto-temporal and parieto-occipital regions, not associated with  any specific neurotransmitter distribution, exhibited reduced GMV in both TRS and non-TRS groups vs. HC (F = 7.239, p < 0.001, FDR-corrected). Amidst the generic GMV reduction that is shared with non-TRS patients, patients with TRS have specific prefrontal-limbic structural deficits with a unique non-dopaminergic chemoarchitecture. These findings indicate a putative molecular and structural basis for poor treatment response, guiding the development of second- and third-line pharmacotherapies for TRS.